Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.53 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.53 |
| ▸ | KDM6B | O15054 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KDM4A | O75164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | HNF4A | P41235 | 1/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9847043 | 0.96 | KDM4C (0.56) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL28883633 | 0.91 | KDM4C (0.49) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL30782804 | 0.91 | KDM4C (0.49) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL27961704 | 0.85 | SLC22A12 (0.51) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL946433 | 0.85 | BCAT2 (0.61) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL2222831 | 0.85 | ALDH1A1 (0.50) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL20593569 | 0.85 | KDM4C (0.53) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL23354479 | 0.84 | SLC22A12 (0.54) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL9318380 | 0.84 | SLC22A12 (0.55) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL21056685 | 0.84 | SLC22A12 (0.54) | KDM4CKDM4DKDM6BKDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-112292380-B | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for the treatment of cancer | 因赛特公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-111801322-B | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | 迈阿密大学 | 2024-03-15 | — | — | CN | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-116589401-A | Near-infrared ratio fluorescent probe and application thereof | 山东大学 | 2023-08-15 | — | — | CN | disclosed |
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | disclosed |
| WO-2010044411-A1 | PHENYLISONICOTINIC ACID DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | キッセイ薬品工業株式会社 (JP) | 2010-04-22 | — | — | WO | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| EP-1725101-A1 | 2-PYRIDINYL [7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A] PYRIMIDIN-3-YL] METHANONES | DOV Pharmaceutical Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20050277639-A1 | 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones | DOV PHARMACEUTICAL, INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005084439-A1 | 2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES | DOV PHARMACEUTICAL, INC. (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144841-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | KDM4C 3750/4885KDM4D 3469/4885KDM6B 2799/4885 |
| US-20050277639-A1 | 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones | HTR1A, HTR2B, HTR4 | KDM4C 3400/4885KDM4D 3442/4885KDM6B 4183/4885 |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | KDM4C 3750/4885KDM4D 3469/4885KDM6B 2799/4885 |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | KDM4C 1614/4885KDM4D 1333/4885KDM6B 2426/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | KDM4C 1773/4885KDM4D 1193/4885KDM6B 2483/4885 |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | AVPR1B, HRH4, PRLHR | KDM4C 1390/4885KDM4D 999/4885KDM6B 1665/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | KDM4C 3750/4885KDM4D 3469/4885KDM6B 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.